Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.encep.2020.05.006 http://scihub22266oqcxt.onion/10.1016/j.encep.2020.05.006 32425222!7229964!32425222     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Encephale 2020 ; 46 (3): 169-172 Nephropedia Template TP {{tp|p=32425222|t=2020. Repurposing chlorpromazine to treat COVID-19: The reCoVery study |pdf=|usr=}}{{32425222}} gab.com Text Repurposing chlorpromazine to treat COVID-19: The reCoVery study JO: Encephale http://www.kidney.de/pget.php?&tw=1&pmid=32425222 #FOAvip OBJECTIVES: The ongoing COVID-19 pandemic has caused approximately 2,350,000 infections worldwide and killed more than 160,000 individuals. In Sainte-Anne Hospital (GHU PARIS Psychiatrie & Neuroscience, Paris, France) we have observed a lower incidence of symptomatic forms of COVID-19 among patients than among our clinical staff. This observation led us to hypothesize that psychotropic drugs could have a prophylactic action against SARS-CoV-2 and protect patients from the symptomatic and virulent forms of this infection, since several of these psychotropic drugs have documented antiviral properties. Chlorpromazine (CPZ), a phenothiazine derivative, is also known for its antiviral activity via the inhibition of clathrin-mediated endocytosis. Recentin vitro studies have reported that CPZ exhibits anti-MERS-CoV and anti-SARS-CoV-1 activity. METHODS: In this context, the ReCoVery study aims to repurpose CPZ, a molecule with an excellent tolerance profile and a very high biodistribution in the saliva, lungs and brain. We hypothesize that CPZ could reduce the unfavorable course of COVID-19 infection among patients requiring respiratory support without the need for ICU care, and that it could also reduce the contagiousness of SARS-CoV-2. For this purpose, we plan a pilot, multicenter, randomized, single blind, controlled, phase III therapeutic trial (standard treatment vs. CPZ+standard treatment). CONCLUSION: This repurposing of CPZ for its anti-SARS-CoV-2 activity could offer an alternative, rapid strategy to alleviate infection severity. This repurposing strategy also avoids numerous developmental and experimental steps, and could save precious time to rapidly establish an anti-COVID-19 therapy with well-known, limited and easily managed side effects. Twit Text FOAVip Repurposing chlorpromazine to treat COVID-19: The reCoVery study ????Encephale http://www.kidney.de/pget.php?&tw=1&pmid=32425222 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32425222 #FOAvip English Wikipedia <ref>{{Cite pmid|32425222}}</ref> Repurposing chlorpromazine to treat COVID-19: The reCoVery study #MMPMID32425222 Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chretien F; Gaillard R Encephale 2020[Jun]; 46 (3): 169-172 PMID32425222show ga OBJECTIVES: The ongoing COVID-19 pandemic has caused approximately 2,350,000 infections worldwide and killed more than 160,000 individuals. In Sainte-Anne Hospital (GHU PARIS Psychiatrie & Neuroscience, Paris, France) we have observed a lower incidence of symptomatic forms of COVID-19 among patients than among our clinical staff. This observation led us to hypothesize that psychotropic drugs could have a prophylactic action against SARS-CoV-2 and protect patients from the symptomatic and virulent forms of this infection, since several of these psychotropic drugs have documented antiviral properties. Chlorpromazine (CPZ), a phenothiazine derivative, is also known for its antiviral activity via the inhibition of clathrin-mediated endocytosis. Recentin vitro studies have reported that CPZ exhibits anti-MERS-CoV and anti-SARS-CoV-1 activity. METHODS: In this context, the ReCoVery study aims to repurpose CPZ, a molecule with an excellent tolerance profile and a very high biodistribution in the saliva, lungs and brain. We hypothesize that CPZ could reduce the unfavorable course of COVID-19 infection among patients requiring respiratory support without the need for ICU care, and that it could also reduce the contagiousness of SARS-CoV-2. For this purpose, we plan a pilot, multicenter, randomized, single blind, controlled, phase III therapeutic trial (standard treatment vs. CPZ+standard treatment). CONCLUSION: This repurposing of CPZ for its anti-SARS-CoV-2 activity could offer an alternative, rapid strategy to alleviate infection severity. This repurposing strategy also avoids numerous developmental and experimental steps, and could save precious time to rapidly establish an anti-COVID-19 therapy with well-known, limited and easily managed side effects. |*Drug Repositioning[MESH] |Antiviral Agents/therapeutic use[MESH] |Anxiety/complications/drug therapy/epidemiology/pathology[MESH] |Betacoronavirus/pathogenicity[MESH] |Blood-Brain Barrier/drug effects[MESH] |COVID-19[MESH] |Chlorpromazine/*therapeutic use[MESH] |Clathrin-Coated Vesicles/drug effects[MESH] |Coronavirus Infections/complications/*drug therapy/epidemiology/pathology[MESH] |Disease Progression[MESH] |Dyspnea/drug therapy/epidemiology/pathology/psychology[MESH] |Endocytosis/drug effects[MESH] |France/epidemiology[MESH] |Humans[MESH] |Length of Stay[MESH] |Mortality[MESH] |Pandemics[MESH] |Patient Outcome Assessment[MESH] |Pilot Projects[MESH] |Pneumonia, Viral/complications/*drug therapy/epidemiology/pathology[MESH] |Recovery of Function[MESH] |SARS-CoV-2[MESH] |Single-Blind Method[MESH] |Time-to-Treatment[MESH]Repurposing chlorpromazine to treat COVID-19: The reCoVery study (epmc).pdf DeepDyve Pubget Overpricing